9,662 Shares in Oscar Health, Inc. (NYSE:OSCR) Bought by Aigen Investment Management LP

Aigen Investment Management LP bought a new position in Oscar Health, Inc. (NYSE:OSCR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 9,662 shares of the company’s stock, valued at approximately $205,000.

Other large investors have also recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd acquired a new position in shares of Oscar Health during the second quarter worth about $78,000. Quest Partners LLC bought a new stake in Oscar Health in the 2nd quarter valued at approximately $93,000. Amalgamated Bank boosted its position in Oscar Health by 27.7% during the 2nd quarter. Amalgamated Bank now owns 6,727 shares of the company’s stock worth $106,000 after acquiring an additional 1,458 shares during the last quarter. Optimum Investment Advisors bought a new position in shares of Oscar Health during the 3rd quarter worth approximately $142,000. Finally, Farallon Capital Management LLC acquired a new stake in shares of Oscar Health in the first quarter valued at approximately $164,000. Institutional investors own 75.70% of the company’s stock.

Oscar Health Stock Down 3.7 %

Oscar Health stock opened at $14.87 on Friday. Oscar Health, Inc. has a fifty-two week low of $6.93 and a fifty-two week high of $23.79. The firm has a market capitalization of $3.60 billion, a PE ratio of -247.83 and a beta of 1.67. The company’s 50-day moving average is $18.20 and its 200-day moving average is $18.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.73 and a quick ratio of 0.91.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.02). Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. The business had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.33 billion. During the same period last year, the firm earned ($0.29) EPS. Oscar Health’s quarterly revenue was up 68.3% compared to the same quarter last year. Sell-side analysts anticipate that Oscar Health, Inc. will post -0.01 earnings per share for the current year.

Insider Activity at Oscar Health

In related news, CAO Victoria Baltrus sold 4,226 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $17.99, for a total value of $76,025.74. Following the transaction, the chief accounting officer now owns 140,648 shares in the company, valued at approximately $2,530,257.52. This represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Vice Chairman Joshua Kushner acquired 276,040 shares of the business’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $13.58 per share, with a total value of $3,748,623.20. Following the completion of the transaction, the insider now directly owns 5,031,262 shares of the company’s stock, valued at approximately $68,324,537.96. The trade was a 5.80 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 1,055,478 shares of company stock worth $14,432,852 and have sold 169,569 shares worth $3,007,069. 25.11% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on OSCR. Bank of America cut shares of Oscar Health from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $21.00 to $13.50 in a report on Wednesday, November 6th. Piper Sandler restated an “overweight” rating and issued a $28.00 price objective on shares of Oscar Health in a report on Tuesday, September 10th. Finally, UBS Group started coverage on Oscar Health in a research report on Monday, October 7th. They issued a “neutral” rating and a $23.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Oscar Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.93.

Oscar Health Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.